Navigation Links
Large Blinded Clinical Study Achieves High Accuracy for the Diagnosis of Melanoma Using In Vivo Confocal Microscopy
Date:9/18/2007

- Lesions non-invasively imaged in 5 to 10 minutes -

- Landmark Study Reported in Journal of Investigative Dermatology -

ROCHESTER, N.Y., Sept. 18 /PRNewswire/ -- A landmark publication that appeared in the Journal of Investigative Dermatology reports the results of a large, two site blinded clinical study. The paper is entitled "The Impact of In Vivo Reflectance Confocal Microscopy for the Diagnostic Accuracy of Melanoma and Equivocal Melanocytic Lesions."

The study, lead by Dr. Giovanni Pellacani, contained a total of 351 equivocal melanocytic lesions that were difficult for expert dermoscopists to diagnose. 136 of the 351 lesions were malignant melanomas. The highest sensitivity demonstrated by confocal microscopy was 96.3%. The highest accuracy corresponded to a sensitivity of 91.9% and a specificity of 69.3%. The standard of comparison for the study was biopsy of all 351 lesions, followed by traditional pathological examination.

"By giving reliable diagnostic information comparable to histology, confocal imaging represents the only feasible alternative to biopsy in the decision-making process faced by dermatologists examining melanocytic lesions," said Dr. Giovanni Pellacani, Department of Dermatology, University of Modena and Reggio Emilia, Modena, Italy, one of the world's leading in-vivo confocal imaging medical researchers. "Consequently, in vivo confocal microscopy is used at Modena and in several other melanoma clinics in Europe for the analysis of melanocytic lesions," Dr. Pellacani continued.

Images Acquired from Lucid VivaScopes(R) in 5 to 10 minutes

"The images in this study were acquired using VivaScope(R) confocal microscopes developed and manufactured by Lucid Inc., of Rochester, New York," said Jay Eastman, Ph.D., Chairman and CEO of Lucid, Inc. "This study represents a major clinical milestone in the transition of confocal imaging from a basic research tool to a diagnostic medical device being used routinely for evaluation of melanocytic lesions. Imaging a single lesion using the VivaScope(R) required just 5 to 10 minutes according to the authors," continued Eastman, "which makes it practical for everyday use in private dermatology practices worldwide."

Study Detailed in the Journal of Investigative Dermatology

The entire paper recounting the study can be found in the Journal of Investigative Dermatology (2007), 0, 000-000, doi: 10.1038/sj.jid.5700993, "The Impact of In Vivo Reflectance Confocal Microscopy for the Diagnostic Accuracy of Melanoma and Equivocal Melanocytic Lesions," authors Giovanni Pellacani, Pascale Guitera, Caterina Longo, Michelle Avramidis, Stefania Seidenari and Scott Menzies. On the Web, visit http://dx.doi.org/10.1038/sj.jid.5700993 .

Authors Pellacani, Longo, and Seidenari are of the Department of Dermatology, University of Modena and Reggio Emilia, Modena, Italy. Guitera, Avramidis, and Menzies are of the Faculty of Medicine, Sydney Melanoma Diagnostic Centre, Sydney Cancer Centre and Dermatology Department, Royal Prince Alfred Hospital, University of Sydney, Sydney, Australia.

This paper builds on the results of an earlier pilot study that was published in the December 2005 issue of the Journal of the American Academy of Dermatology, beginning on page 979 of that issue.

About Lucid Inc.

Lucid Inc., based in Rochester, New York, USA, is a medical device and information company dedicated to creating innovative cellular imaging technology and using the Internet to securely deliver accurate, real-time VivaScope(R) cellular resolution images to medical professionals. When coupled with its digital VivaNet(TM) system, the company's ability to image in-vivo (living) tissue will aid medical practitioners and pathologists in skin cancer screening with clarity, speed and patient comfort. For more information about Lucid Inc., visit http://www.Lucid-tech.com . Available Topic Expert(s): For information on the listed expert(s), click appropriate link. Jay Eastman, Ph.D. http://profnet.prnewswire.com/Subscriber/ExpertProfile.aspx?ei=62055


'/>"/>
SOURCE Lucid Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine technology :

1. Urinalysis Analyzers: Large Capabilities in Every Size Device
2. Large Geographic Differences in EpiPen Prescriptions in the U.S., From the Journal of Allergy and Clinical Immunology
3. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
4. Largest Cervical Cancer Vaccine Efficacy Trial Shows Cervarix Provides Excellent Protection Against Lesions Caused by Most Common Cancer-Causing Virus Types
5. Largest National U.S. Healthcare Facility MRSA Study Reveals Infection Rates Eight Times Greater Than Previous Estimates
6. Newly Published Data from Large Study Support Cardiovascular Safety of Avandia (Rosiglitazone Maleate)
7. MedImmune Announces Positive Clinical Results at PAS Annual Meeting From Large Prospective Trial in Prevention of Serious RSV Disease
8. First Controlled Large-Scale Intervention Angiotensin Receptor Blocker (ARB) Trial in a Japanese Population, JIKEI HEART Study Demonstrates Significant Reduction in Blood Pressure and Protection of Organs with Valsartan
9. Large Study Shows that Presence of Neutralizing Antibodies Did Not Predict Clinical Response to Betaseron Treatment
10. Medical Journal Publishes First Large-Scale Survey Revealing Experiences of IPF Patients
11. Based on Up to 6 Years of Follow-Up, Biovest Announces Favorable Interim Blinded Data for Fast-Tracked Pivotal Phase 3 Clinical Trial of BiovaxID Anti-Cancer Vaccine for Non-Hodgkins Lymphoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2016)... LAWRENCE, Mass. , May 24, 2016  NxStage ... medical technology company focused on advancing renal care, today ... Officer, plans to participate in the following schedule of ... will be made available at http://ir.nxstage.com/ . ... Jefferies Healthcare Conference NY, NY           Friday, ...
(Date:5/24/2016)... May 24, 2016  Joe Marziani has joined VMS BioMarketing as senior vice president ... today. In his new role, Marziani will lead the company,s business development and sales ... improve outcomes. Photo - http://photos.prnewswire.com/prnh/20160523/371089 ... ... ...
(Date:5/24/2016)... , May 24, 2016 ... doble terapia del mundo, introduce catéteres para la ... OrbusNeich, una compañía global especializada en el ... ha expandido su cartera incluyendo productos para tratar ... y Scoreflex™ PTA son los dispositivos de primera ...
Breaking Medicine Technology:
(Date:5/24/2016)... ... May 24, 2016 , ... ... Cifolelli has joined the company as Vice President of Sales. Cifolelli’s primary ... and international sales in the rapidly expanding field of organizational social engineering. ...
(Date:5/24/2016)... ... May 24, 2016 , ... i2i, ... identity and website at its “Transforming Outcomes” User Conference in Las Vegas on ... i2i’s ongoing success to set the market standard for meaningful population health management. ...
(Date:5/24/2016)... ... May 24, 2016 , ... Educational opportunities, ... housing, with more advantaged communities providing richer opportunities. Recognizing the key role of ... school improvement policies; (b) school choice policies; (c) school desegregation policies; (d) wealth-focused ...
(Date:5/24/2016)... Georgia (PRWEB) , ... May 24, 2016 , ... Mental ... 1969 by the Church of Scientology and renowned professor of psychiatry Thomas Szasz, is ... of its “Psychiatry: An Industry of Death” exhibit in Atlanta, Georgia. The opening of ...
(Date:5/24/2016)... NY (PRWEB) , ... May 24, 2016 , ... ... treatment for physical disease or injury that focuses on repairing the musculoskeletal and ... , With an emphasis on functional restoration, NYDNRehab began providing treatments for physical ...
Breaking Medicine News(10 mins):